

29 April 2020

Our Ref: RFI 34206

Dear

**Freedom of Information Act 2000
Information in Relation to Osteoporosis - Drugs prescribed to females over 50**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 30 March 2020.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

**Joyce Batch
Information Governance Assistant**

Q1. In the past 3 months, how many over 50s females have you treated with a drug [eg biphosphonate, denosumab, raloxifene or teriparatide] for osteoporosis?

A1. The Trust is unable to provide this level of detail as we do not have an electronic prescribing and administration system.

Q2. In the past 3 months how many patients were treated with:
a) Forsteo [teriparatide]
b) Movymia [teriparatide]
c) Terrosa [teriparatide]

A2.

- a) 26 patients were treated with Forsteo.
- b) Movymia is not stocked by the Trust.
- c) Terrosa is not stocked by the Trust.

Q3. If possible; of these patients how many were new to the treatment, ie had not previously been treated with teriparatide?
a) Forsteo [teriparatide]
b) Movymia [teriparatide]
c) Terrosa [teriparatide]

A3.

- a) 26 patients were treated with Forsteo.
- b) Movymia is not stocked by the Trust.
- c) Terrosa is not stocked by the Trust.